Allogene Therapeutics (ALLO) Non Operating Income (2018 - 2026)

Allogene Therapeutics has reported Non Operating Income for 9 years, with the latest figure at $3.5 million in Q1 2026.

• Quarterly Non Operating Income fell 36.15% year-over-year to $3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.5 million (down 3.23% YoY) and the FY2025 annual result came in at $18.4 million, up 14.81% from the prior year.
• Non Operating Income slipped to $3.5 million in Q1 2026 per ALLO's latest filing, from $3.6 million in the prior quarter.
• Over five years, Non Operating Income peaked at $5.9 million in Q2 2025 and troughed at -$3.7 million in Q2 2022.
• A 5-year average of $2.1 million and a median of $3.5 million in 2026 frame the typical range for Non Operating Income.
• The sharpest annual moves came in 2022 and 2024: Non Operating Income sank 4050.54% in 2022, then soared 673.06% in 2024.
• Over 5 years, Non Operating Income stood at -$880000.0 in 2022, then gained by 23.98% to -$669000.0 in 2023, then jumped by 248.58% to $994000.0 in 2024, then jumped by 261.57% to $3.6 million in 2025, then retreated by 3.03% to $3.5 million in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered $3.5 million, $3.6 million, and $3.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.